Table 1 Baseline characteristics of older patients with or without PE.
Data | Overall cohort | Propensity score matched cohort | ||||||
|---|---|---|---|---|---|---|---|---|
PE group (n = 86) | Control group (n = 3,420) | t/χ2 value | P value | PE group (n = 53) | Control group (n = 53) | t/χ2 value | P value | |
Basic characteristics | ||||||||
Age(years) | 79.3 ± 12.7 | 75.2 ± 9.1 | 4.080 | <0.001 | 77.4 ± 10.8 | 77.2 ± 6.4 | 0.647 | 0.519 |
Male | 58(67.4%) | 2094(61.2%) | 1.397 | 0.237 | 29(54.7%) | 28(52.8%) | 0.038 | 0.846 |
BMI (kg/m2) | 22.7 ± 4.9 | 23.5 ± 4.2 | 1.737 | 0.083 | 22.1 ± 3.5 | 22.5 ± 2.7 | −0.659 | 0.512 |
Smoking | 52(60.4%) | 1941(56.8%) | 0.474 | 0.491 | 37(69.8%) | 33(62.3%) | ||
Medical history | ||||||||
Hypertension | 31(36.0%) | 1345(39.3%) | 0.383 | 0.536 | 17(32.1%) | 19(35.8%) | 0.168 | 0.682 |
Diabetes | 35(40.7%) | 989(28.9%) | 5.659 | 0.017 | 15(28.3%) | 17(32.1%) | 0.179 | 0.672 |
COPD | 42(48.8%) | 1294(37.8%) | 4.192 | 0.041 | 33(62.3%) | 31(58.5%) | 0.158 | 0.691 |
Atrial fibrillation | 22(25.6) | 603(17.6) | 3.619 | 0.057 | 18(34.0%) | 10(18.9%) | 3.106 | 0.078 |
Varicose veins | 26(30.2%) | 665(19.4%) | 5.541 | 0.019 | 19(35.8%) | 13(24.5%) | 1.389 | 0.239 |
Deep vein catheterization | 36(41.8%) | 1073(31.4%) | 4.072 | 0.044 | 18(34.0%) | 14(26.4%) | 0.718 | 0.397 |
DVT | 44(51.2%) | 295(8.6%) | 99.394 | <0.001 | 31(58.5%) | 29(54.7%) | 0.154 | 0.695 |
Lab. test | ||||||||
D-Dimer (ug/L) | 601.3 ± 282.2 | 399.5 ± 375.4 | 4.949 | <0.001 | 532.3 ± 162.4 | 489.9 ± 185.7 | 1.251 | 0.214 |
WBC count (×109/L) | 8.92 ± 5.64 | 8.21 ± 5.97 | 1.088 | 0.277 | 8.6 ± 3.7 | 8.5 ± 4.1 | 0.132 | 0.895 |
Hemoglobin (g/L) | 110.6 ± 49.3 | 131.2 ± 75.7 | 2.510 | 0.012 | 111.6 ± 26.8 | 127.7 ± 32.5 | 2.782 | 0.401 |
Platelet count (×109/L) | 182.3 ± 137.4 | 237.4 ± 199.8 | 2.544 | 0.011 | 226.6 ± 86.2 | 234.5 ± 99.1 | 0.438 | 0.662 |
PaO2 (mmHg) | 68.2 ± 33.8 | 76.7 ± 32.7 | 2.379 | 0.017 | 72.2 ± 21.3 | 79.7 ± 12.4 | 1.233 | 0.220 |
Hemodynamic parameters | ||||||||
SBP (mmHg) | 107.8 ± 44.5 | 125.4 ± 42.7 | 3.771 | 0.0002 | 109.7 ± 12.3 | 113.6 ± 15.3 | 1.446 | 0.151 |
DBP (mmHg) | 62.4 ± 26.3 | 70.6 ± 17.5 | 4.227 | <0.001 | 68.5 ± 10.5 | 71.4 ± 8.5 | 1.563 | 0.121 |
Heart rate | 113.7 ± 47.5 | 93.2 ± 43.7 | 4.287 | <0.001 | 101.6 ± 13.3 | 98.2 ± 9.6 | 1.509 | 0.134 |
Clinical TNM stage | 12.013 | 0.002 | 1.851 | 0.396 | ||||
I-II | 11(12.8%) | 427(3.7%) | 16(30.2%) | 10(18.9%) | ||||
III | 41(47.7%) | 1870(54.7%) | 23(43.4%) | 27(50.9%) | ||||
IV | 34(39.5%) | 1123(41.6%) | 14(26.4%) | 16(30.2%) | ||||
Histology | 6.324 | 0.042 | 1.325 | 0.516 | ||||
Adenocarcinoma | 47(54.6%) | 1974(58.0%) | 28(52.8%) | 23(43.4%) | ||||
Squamous cell carcinoma | 22(25.6%) | 1081(31.6%) | 17(32.1%) | 18(34.0%) | ||||
Large cell carcinoma | 17(19.8%) | 365(10.4%) | 8(15.1%) | 12(22.6) | ||||
Treatment (%) | ||||||||
Surgery | 33(38.3%) | 973(26.7%) | 3.820 | 0.051 | 20(37.7%) | 19(35.9%) | 0.041 | 0.840 |
Chemotherapy | 83(96.5%) | 3176(92.9%) | 2.057 | 0.151 | 51(96.2%) | 50(94.3%) | 0.211 | 0.646 |
Targeted therapy | 24(27.9%) | 745(21.7%) | 1.735 | 0.188 | 13(24.5%) | 15(28.3%) | 0.194 | 0.659 |
Radiation | 35(37.2%) | 1026(30.0%) | 1.993 | 0.158 | 16(30.2%) | 18(34.0%) | 0.173 | 0.677 |
Anti-coagulation | 61(70.9%) | 155(4.5) | 256.699 | <0.001 | 37(69.8%) | 28(52.8%) | 3.767 | 0.052 |
Thrombolysis | 12(13.9%) | 29(0.8) | 42.381 | <0.001 | 7(13.2%) | 2(3.8%) | 3.200 | 0.074 |
